BIODESIX INC
BDSXNasdaq
$20.19
↑ +1.2%Jul 17 close · end-of-day
Price
1Y↑ +229.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$195.0M
Enterprise Value
$219.4M
P/E
—
P/S
2.0
P/B
21.3
EV/EBITDA
—
PEG
—
FCF Yield
-12.9%
Dividend Yield
—
Revenue (TTM)
$96.1M
Net Income (TTM)
-$32.0M
Free Cash Flow (TTM)
-$25.1M
Gross Margin
—
Operating Margin
-25.9%
Net Margin
-33.3%
ROE
-350.0%
ROIC
-58.7%
Debt / Equity
5.5
Net Cash
-$24.4M
Return 1Y
+225.0%
Company profile
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- CEO
- Scott Hutton
- Sector
- Services
- Industry
- Healthcare
- Employees
- 220
- Headquarters
- Colorado
- Website
- biodesix.com
Management & directors
- Cowie Robin HarperCFO, Sec'y & Treasurer
- Hutton ScottPresident & CEO
- O'Kane KieranChief Commercial Officer
- Pestano Gary AnthonyChief Development Officer
- Vazquez ChrisChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
BDSX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$25.6M↑ +42.3%
Diluted EPS-$0.81↓ -46.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.9M | -$40.9M | -$50.6M | -$41.3M | -$34.5M | -$27.9M |
| Net income | -$65.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Diluted EPS | — | -$1.58 | -$1.55 | -$0.64 | -$6.64 | -$4.67 |
| Operating cash flow | -$21.4M | -$28.2M | -$45.0M | -$22.9M | -$48.6M | -$23.3M |
| Free cash flow | -$23.3M | -$30.5M | -$48.3M | -$45.8M | -$51.9M | -$23.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% |
| Net margin | -143.7% | -79.2% | -171.3% | -106.2% | -60.2% | -39.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.9M | $18.2M | $20.4M | $18.0M | $20.0M | $21.8M | $28.8M | $25.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.2M | -$8.6M | -$6.6M | -$9.1M | -$9.7M | -$7.1M | -$2.0M | -$6.2M |
| Net income | -$10.8M | -$10.3M | -$8.3M | -$11.1M | -$11.5M | -$8.7M | -$4.0M | -$7.8M |
| Diluted EPS | -$0.08 | -$1.40 | -$5.02 | -$1.52 | -$0.08 | -$1.16 | -$1.91 | -$0.81 |
| Operating cash flow | -$18.6M | -$10.7M | -$4.1M | -$8.6M | -$6.6M | -$8.9M | $778,000.00 | -$10.2M |
| Free cash flow | -$20.5M | -$10.9M | -$4.9M | -$8.7M | -$6.6M | -$8.9M | $692,000.00 | -$10.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -46.0% | -47.3% | -32.5% | -50.9% | -48.6% | -32.4% | -6.8% | -24.3% |
| Net margin | -60.3% | -56.5% | -40.4% | -61.8% | -57.3% | -40.0% | -13.9% | -30.5% |
Company news
Jul 1, 2026
Jun 26, 2026
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | PATIENCE JOHN | Option exercise | 1,361 | — | — | filing |
| 2026-03-31 | PATIENCE JOHN | Option exercise | 1,361 | — | — | filing |
| 2026-02-23 | Hutton Scott· President & CEO | Sale | 1,490 | $12.78 | $19,035.64 | filing |
| 2026-02-23 | Pestano Gary Anthony· Chief Development Officer | Sale | 556 | $12.78 | $7,103.23 | filing |
| 2026-02-23 | Cowie Robin Harper· CFO, Sec'y & Treasurer | Sale | 535 | $12.78 | $6,834.95 | filing |
| 2026-02-23 | O'Kane Kieran· Chief Commercial Officer | Sale | 535 | $12.78 | $6,834.95 | filing |
| 2026-02-23 | Vazquez Chris· Chief Accounting Officer | Sale | 211 | $12.78 | $2,695.65 | filing |
| 2026-02-20 | Pestano Gary Anthony· Chief Development Officer | Option exercise | 1,528 | — | — | filing |
| 2026-02-20 | O'Kane Kieran· Chief Commercial Officer | Option exercise | 1,469 | — | — | filing |
| 2026-02-20 | Vazquez Chris· Chief Accounting Officer | Option exercise | 563 | — | — | filing |
| 2026-02-20 | Hutton Scott· President & CEO | Option exercise | 4,844 | — | — | filing |
| 2026-02-20 | Cowie Robin Harper· CFO, Sec'y & Treasurer | Option exercise | 1,469 | — | — | filing |
| 2026-02-10 | Hutton Scott· President & CEO | Sale | 3,559 | $10.08 | $35,889.31 | filing |
| 2026-02-10 | Cowie Robin Harper· CFO, Sec'y & Treasurer | Sale | 941 | $10.08 | $9,489.14 | filing |
| 2026-02-10 | O'Kane Kieran· Chief Commercial Officer | Sale | 584 | $10.08 | $5,889.11 | filing |
| 2026-02-10 | Pestano Gary Anthony· Chief Development Officer | Sale | 540 | $10.08 | $5,445.41 | filing |
| 2026-02-10 | Vazquez Chris· Chief Accounting Officer | Sale | 101 | $10.08 | $1,018.49 | filing |
| 2026-02-09 | Hutton Scott· President & CEO | Option exercise | 9,998 | — | — | filing |
| 2026-02-09 | Cowie Robin Harper· CFO, Sec'y & Treasurer | Option exercise | 2,584 | — | — | filing |
| 2026-02-09 | Pestano Gary Anthony· Chief Development Officer | Option exercise | 1,481 | — | — | filing |
| 2026-02-09 | O'Kane Kieran· Chief Commercial Officer | Option exercise | 1,600 | — | — | filing |
| 2026-02-09 | Vazquez Chris· Chief Accounting Officer | Option exercise | 263 | — | — | filing |
| 2026-01-26 | SCHULER JACK W | Buy | 20,000 | $11.80 | $236,064.00 | filing |
| 2026-01-23 | SCHULER JACK W | Buy | 80,000 | $11.81 | $944,672.00 | filing |
| 2026-01-22 | SCHULER JACK W | Buy | 82,465 | $10.96 | $903,560.76 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.